Plano, Texas — February 10, 2026: Vesalio, a global vascular intervention medical device company, announced major regulatory and commercial milestones with CE Mark certification for NeVa™ VS and NeVa™ 3.0 mm thrombectomy systems alongside an additional U.S. FDA 510(k) clearance for expanded indications of its aspiration catheter portfolio. The dual regulatory achievements strengthen the company’s neuro-interventional footprint across Europe and the United States, advancing treatment technologies for stroke and cerebral vasospasm.
Science Significance
The newly certified neurovascular devices represent significant advancements in mechanical thrombectomy and vasospasm intervention science. NeVa™ VS is engineered to treat cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH)—a life-threatening complication that can lead to delayed cerebral ischemia and neurological decline. Unlike balloon angioplasty, the device preserves distal blood flow while restoring vessel patency. Clinical evidence from the VITAL study demonstrated 93.2% of treated vessels required no further intervention, highlighting its therapeutic precision. Meanwhile, the NeVa™ 3.0 mm thrombectomy system expands the company’s Drop Zone™ clot retrieval technology to smaller and more tortuous arteries, increasing procedural reach and enhancing first-pass clot removal success in acute ischemic stroke interventions.
Regulatory Significance
The announcement underscores robust progress across global device regulatory pathways. CE Mark certification enables commercial distribution of NeVa™ VS and NeVa™ 3.0 mm systems across European markets under medical device regulatory compliance frameworks. In parallel, the FDA 510(k) clearance expands labeled indications for Vesalio’s neurovascular and peripheral aspiration catheters to include distal access with microcatheter delivery, validating safety and performance equivalence. NeVa™ VS had previously received U.S. authorization via a Humanitarian Device Exemption (HDE), reinforcing its regulatory credibility in treating rare but critical neurovascular conditions. Collectively, these approvals reflect continued adherence to design validation, clinical evaluation, and quality system requirements governing high-risk interventional devices.
Business Significance
Advertisement
From a commercial strategy perspective, the regulatory wins mark Vesalio’s seventh CE certification and further diversify its neurovascular product portfolio. Expanded device indications and new European launches support global market penetration while strengthening physician adoption across stroke and neurovascular centers. The milestones position the company for accelerated international commercialization, portfolio scalability, and revenue growth. Leadership emphasized that regulatory progress achieved in 2025 and early 2026 supports the company’s transition into its next phase of operational and commercial expansion, reinforcing investor confidence and competitive positioning in the neuro-intervention device sector.
Patients’ Significance
For patients, the expanded device portfolio enhances access to minimally invasive, life-saving stroke and vasospasm treatments. Cerebral vasospasm following aSAH remains associated with high morbidity and mortality, and safer alternatives to angioplasty are critically needed. NeVa™ VS offers controlled vessel dilation while preserving downstream perfusion, potentially reducing neurological complications. Similarly, the NeVa™ 3.0 mm system expands eligibility for mechanical thrombectomy in patients with smaller vessel occlusions, improving treatment access and functional recovery outcomes. Enhanced catheter versatility also supports more precise distal clot aspiration, contributing to faster reperfusion and improved stroke survival rates.
Policy Significance
The regulatory expansion aligns with broader healthcare policy priorities aimed at improving stroke response infrastructure, neurovascular intervention access, and advanced device innovation. Stroke remains a leading cause of death and long-term disability globally, prompting continued investment in interventional technologies that improve treatment speed and outcomes. Cross-regional approvals such as CE Mark and FDA clearance support regulatory harmonization, accelerate technology adoption, and strengthen international medical device innovation ecosystems focused on high-burden neurological diseases.
Vesalio’s latest CE certifications and FDA clearance signal sustained innovation momentum in neurovascular intervention and mechanical thrombectomy technologies. By expanding device capabilities across vasospasm and stroke care, the company reinforces its role in advancing minimally invasive vascular treatment science. Continued regulatory validation, clinical adoption, and global commercialization are expected to drive next-generation neuro-interventional solutions that improve both physician capability and patient survival outcomes.
Source: Vesalio press release
